Search Results - Endovascular Today

Sponsored by Cardiovascular Systems, Inc.

evt | Article | September 2017

Long-Term Data From Liberty 360° Show Positive Impact for Patients Receiving Endovascular Therapy

A roundtable discussion of the real-world LIBERTY 360° 12-month data and the study's significance in treating patients with peripheral artery disease and critical limb ischemia.

With Ehrin J. Armstrong, MD; Jihad A. Mustapha, MD; George A. Pliagas, MD; and Jason A. Yoho, MD

evt | News | June 3, 2019

Findings Presented That Show Luminal Gain With VentureMed's Flex VP System

June 4, 2019—VentureMed Group, Inc. announced that new data for the company's Flex VP vessel preparation system were presented at the 20th Annual New Cardiovascular Horizons (NCVH) annual conference held May 29–31 in New Orleans, Louisiana.

evt | Article | October 2023

The Auryon Atherectomy System in Practice: An Essential Tool for Treating Severely Calcified Lesions

Jason Yoho, MD, discusses his experience with the Auryon Atherectomy System, how the forthcoming data from the PATHFINDER I postmarket registry correlate with what he has seen in clinical practice, and the device’s role in treating calcified plaque.

evt | Article | November 2020

Case Reports: The Auryon Atherectomy System Above and Below the Knee

A discussion of the PATHFINDER I postmarket trial and case experience from two centers demonstrating successful use of the Auryon laser in severely calcified lesions.

With Jason Yoho, MD, FACC; Venkatesh Ramaiah, MD, FACS; and Harrison Lewis, DMSc, MS, PA-C

evt | News | August 17, 2020

Postmarket PATHFINDER I Registry Commences for AngioDynamics’ Auryon Atherectomy System

August 17, 2020—AngioDynamics, Inc. announced the enrollment of the first patient in the postmarket PATHFINDER I registry, which is a pilot study designed to evaluate the safety and efficacy of the company’s Auryon atherectomy system in the real-world treatment of de novo, restenotic, and in-stent restenosis (ISR) lesions in infrainguinal arteries of patients with peripheral artery disease (PAD).

evt | News | December 1, 2020

Vesper Medical Announces Initiation of Pivotal VIVID Trial for the Vesper Duo Venous Stent System

December 1, 2020—Vesper Medical, Inc. announced the initiation of VIVID, its FDA investigational device exemption (IDE) study of the company’s Vesper Duo venous stent system, with the enrollment of the first patient.

evt | News | August 3, 2016

Mercator MedSystems Begins LIMBO-ATX Trial for Bullfrog Microinfusion Device to Treat CLI

August 4, 2016—Mercator MedSystems, Inc. has begun enrollment in the LIMBO-ATX critical limb ischemia (CLI) trial, which is designed to measure the benefit of localized drug delivery using the company’s Bullfrog microinfusion device in combination with opening obstructed arteries in the lower leg.